Chronic spontaneous urticaria in Russia: the patient journey

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: There is no data on the nature of medical care provided to patients with chronic spontaneous urticaria from the patient’s perspective.

AIM: To analyze the clinical and social aspects of chronic spontaneous urticaria and the patterns of healthcare delivery using data from an online survey of patients from 63 cities across Russia.

METHODS: A structured online survey was performed among respondents with chronic spontaneous urticaria over the age of 18. The survey was conducted between April and June 2025 and included 40 questions covering demographic characteristics, disease severity, comorbidities, patient routing, medical visits, and treatment of chronic spontaneous urticaria. The data were analyzed quantitatively, with the calculation of the proportions of responses for each question from patients in 63 cities across Russia. IBM SPSS Statistics 21 was used for statistical analysis.

RESULTS: The study involved 1,061 patients with chronic spontaneous urticaria. Most of them of working age; more than 60 % did not achieve control according to the chronic spontaneous urticaria test. Common comorbidities were sleep disorders and anxiety disorders. Patients consulted several specialists before diagnosis; an allergist-immunologist played a leading role in the management of chronic spontaneous urticaria. Satisfaction with standard-dose antihistamines was low, and the availability of second-line therapy was limited.

CONCLUSION: The results highlight the need to improve patient referral pathways, increase physicians’ awareness of the principles of diagnosis and management of chronic spontaneous urticaria, enhance access to modern therapeutic options, and promote a multidisciplinary approach to chronic spontaneous urticariamanagement. Overall, the findings are consistent with international studies while also providing insight into the specific features of chronic spontaneous urticariamanagement in the Russian healthcare setting.

About the authors

Inna V. Danilycheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency

Author for correspondence.
Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948
Russian Federation, Moscow

Olesia S. Mishina

Childrens Scientific and Clinical Center named after L.M. Roshal

Email: olesya.mishina@mail.ru
ORCID iD: 0000-0003-1172-4568
SPIN-code: 5365-9340
Russian Federation, Krasnogorsk, Moscow region

Ilia А. Bogdanov

European University at St. Petersburg

Email: Ilya.SCI@yandex.ru
ORCID iD: 0009-0008-0304-5550
SPIN-code: 5926-8255
Russian Federation, St. Petersburg

Andrey E. Shulzhenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency

Email: shulzhenko_ae@mail.ru
ORCID iD: 0000-0003-0268-9350
SPIN-code: 4584-4915
Russian Federation, Moscow

References

  1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090 EDN: NEWKMD
  2. Kolkhir P, Church MK, Altrichter S, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2021;147(6):1749–1761. doi: 10.1016/j.jaci.2021.03.016
  3. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819–1831. doi: 10.1016/j.jaci.2022.04.010 EDN: PPUMXY
  4. Puhl V, Bonnekoh H, Scheffel J, et al. A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clin Transl Allergy. 2021;11(2):e12031. doi: 10.1002/clt2.12031 EDN: NVLMQS
  5. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869–873. doi: 10.1111/j.1398-9995.2004.00473.x EDN: FLSDAQ
  6. Brazovskaya NG, Deev IA, Kobyakova OS, et al. Patient-centered approach: analysis of relationship between effectiveness of medical care and conditions of its provision as estimated by patients. Social Aspects of Population Health. 2019;65(5):1. (In Russ.) doi: 10.21045/2071-5021-2019-65-5-1 EDN: EKCYEL
  7. Bernstein JA, Winders TA, McCarthy J, et al. Urticaria voices: real-world treatment patterns and outcomes in chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2025;15(8):2201–2215. doi: 10.1007/s13555-025-01461-8 EDN: ONWTGO
  8. Danilycheva I, Emelyanov A, Meshkova R, et al. Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study. Postepy Dermatol Alergol. 2022;39(3):509–516. doi: 10.5114/ada.2022.117556 EDN: JKYPDF
  9. Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8(6): 551–558. doi: 10.1007/s40271-015-0145-9 EDN: XNCNAI
  10. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016. doi: 10.1111/all.13209
  11. Darlensky R, Kazandjieva J, Zuberbier T, Tsankov N. Chronic urticaria as a systemic disease. Clin Dermatol. 2013;32(3):420–423. doi: 10.1016/j.clindermatol.2013.11.009
  12. Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real-life data from a multicenter observational study focusing on elderly patients. Dermatol Ther. 2021;34(2):e14841. doi: 10.1111/dth.14841 EDN: YXVLVF
  13. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533. doi: 10.1016/j.waojou.2021.100533 EDN: DYGDZY
  14. Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655–662. doi: 10.1111/cea.13309 EDN: AOQBDB
  15. Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984–994. doi: 10.1056/NEJMoa2408792 EDN: DGDCYY
  16. Giménez-Arnau AM, Szalewski R, Hide M, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. J Allergy Clin Immunol. 2026;157(1):143–154. doi: 10.1016/j.jaci.2025.09.028 EDN: BTJQHJ
  17. Maurer M, Casale TB, Saini SS. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184–194. doi: 10.1016/j.jaci.2024.01.028 EDN: YRHSWE
  18. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Up-dosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: 10.1111/bjd.14768

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © ABV-press, 2026

License URL: https://rusalljournal.ru/raj/about/submissions#copyrightNotice

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.